Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > Intensive co-located smoking cessation programme highly effective during lung screening

Intensive co-located smoking cessation programme highly effective during lung screening

Presented By
Prof. Rachael Murray, University of Nottingham, UK
Conference
WCLC 2022
Trial
YESS
Doi
https://doi.org/10.55788/017187ab
Co-located smoking cessation support during a lung health check leads to high abstinence rates in participants, especially when this 1-on-1 supportive care is continued for several months. In addition, women appear to benefit from additional supportive communication and individualised feedback, the randomised YESS trial indicated [1]. “The addition of tobacco treatment to lung cancer screening reduces deaths by an additional 14%, providing a fantastic opportunity to make real health gains [2],” argued Prof. Rachael Murray (University of Nottingham, UK). “However, it remains unclear what type of smoking cessation intervention will elicit the largest effect.” The current study invited 2,150 eligible participants who were scheduled for a lung health check to visit a co-located smoking cessation practitioner (SCP) through an opt-out system. Of the eligible participants, 1,609 agreed to receive ongoing support by the SCP and 1,003 were randomised into the YESS ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on